Barclays Maintains Overweight on Sutro Biopharma, Raises Price Target to $57
Barclays analyst Lukas Shumway maintains Sutro Biopharma (NASDAQ:STRO) with a Overweight and raises the price target from $56 to $57.
Last updated: 2026-11-19 07:21:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Sutro Biopharma, Inc. (STRO) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $8.49, with a market capitalization of $148.08M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.15 to $43.85. This page covers its latest market performance, valuation, price trends and company information.
$148.08M | |
$8.85 | |
$9.04 | |
$8.36 | |
$8.92 | |
219.61K | |
304.60K | |
-- | |
$43.85 | |
$7.15 | |
-- | |
2026-09-30 |
Sutro Biopharma, Inc. (STRO) last closed at $8.49 as of 2026-11-19 00:31:00, down 4.60% ($0.41) from the previous close of $8.92.
During the latest regular trading session, STRO traded between $8.36 and $9.04, with a volume of 219.61K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, Sutro Biopharma, Inc. (STRO) moved from $10.17 to $8.49, representing a decline of 16.56% ($1.68).
The stock traded between $8.33 and $10.77 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 303.52 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 3.6%
STRO is currently trading at $8.49, placing it 3.6% of the way from its 52-week low of $7.15 to its 52-week high of $43.85. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 128 |
| Exchange | NASDAQ |
| Company Website |
Latest news related to Sutro Biopharma, Inc. and STRO stock.
Barclays analyst Lukas Shumway maintains Sutro Biopharma (NASDAQ:STRO) with a Overweight and raises the price target from $56 to $57.
Sutro Biopharma (NASDAQ:STRO) reported quarterly losses of $(1.90) per share which beat the analyst consensus estimate of $(1.91) by 0.52 percent. This is a 71.64 percent increase over losses of $(6.70) per share from
Eligible investors can buy real shares of Sutro Biopharma, Inc. (STRO) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to STRO, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between STRO shares and USD.
STRO Shares to USD
1.00 STRO shares = 8.486 USD
Calculations are estimates based on the latest available price and are for reference only.